We investigated studies in which inhibitory molecules, including galactin-12, PPARγ ligands, CDCA, CHR2863, and others, were used to modulate lipid droplet production in cellular models of AML (Figure 2). The gene discussed is PPARG; the disease is acute myeloid leukemia.